MENU

Fox Chase Physician Elizabeth Plimack Elected to Board of American Society of Clinical Oncology

December 17, 2019

"Members of the board guide the focus and goals of the organization, and there are a lot of new challenges facing oncologists today. I hope to be able to address some of those during my time,” said Dr. Plimack. "Members of the board guide the focus and goals of the organization, and there are a lot of new challenges facing oncologists today. I hope to be able to address some of those during my time,” said Dr. Plimack.

PHILADELPHIA (December 17, 2019) – Elizabeth Plimack, MD, MS, professor and chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has been elected to the American Society of Clinical Oncology (ASCO) Board of Directors for a term of four years. She will begin her appointment in June 2020 and is eager to be representing Fox Chase as she works to encourage collaboration and methods of sharing information in oncology.

“I am very enthusiastic about this opportunity. Members of the board guide the focus and goals of the organization, and there are a lot of new challenges facing oncologists today. I hope to be able to address some of those during my time,” said Plimack.

As chief and director of Genitourinary Clinical Research, Plimack believes her experience has given her a unique perspective for her work at ASCO. “At Fox Chase, we have historically been a standalone institution and have a long history of collaborative work in cancer care delivery, clinical research, treatment, and basic research that I hope I can bring to bear while working with ASCO,” she said.

While serving as a board member, Plimack hopes to stress the importance of fostering collaborative models among researchers, as well as integrating patient perspectives and providing better avenues to access information. Additionally, she will encourage ASCO to pursue research on how new information can be shared with clinicians that will allow them to integrate new technologies and information into their workflows more easily. Plimack said she feels that part of her mission is to establish best practices for shared information and how industry interacts with researchers, clinicians, and patients.  

“Social media is growing as a tool to spread information, and misinformation, and we should study different models and consider future best practices for the global dissemination of data,” Plimack said.

A professional medical society of nearly 45,000 members, ASCO works to conquer cancer through research, education, and promotion of the highest quality patient care.

      

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

 

For more information, call 888-369-2427

Connect with Fox Chase